Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 276Neoplasms 255Prostatic Neoplasms 216Colorectal Neoplasms 196Lung Neoplasms 153Multiple Myeloma 148Neoplasm Metastasis 135Ovarian Neoplasms 126Leukemia, Myeloid, Acute 123Pancreatic Neoplasms 116Melanoma 102Squamous Cell Carcinoma of Head and Neck 97Recurrence 85Endometrial Neoplasms 82Carcinoma, Renal Cell 80Glioblastoma 78Lymphoma, Non-Hodgkin 77Stomach Neoplasms 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Lymphoma 72Carcinoma, Hepatocellular 72Glioma 65Brain Neoplasms 65Uterine Cervical Neoplasms 63Sarcoma 63Head and Neck Neoplasms 63Triple Negative Breast Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 58Urinary Bladder Neoplasms 55

Interventions

Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pituitary Diseases × 30 days × Clear all
NCT04042753 2026-06-02

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
10 enrolled
Endocrine

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡